Published: Thu, February 15, 2018
Business | By Tara Barton

The Nektar Therapeutics (NKTR) Shares Bought by Shelton Capital Management

Jennison Associates LLC now owns 3,178,432 shares of the company's stock worth $18,530,000 after buying an additional 1,107,496 shares during the period. Rice Hall James & Associates LLC owned 0.65% of Nektar Therapeutics worth $61,472,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Nektar Therapeutics by 3.0% in the second quarter. In terms of performance, year to date, the stock is 5.90%. Insiders sold a total of 196,666 shares of company stock valued at $12,718,923 in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Nektar Therapeutics by 14.1% during the fourth quarter. Finally, SeaCrest Wealth Management LLC acquired a new stake in shares of Nektar Therapeutics in the fourth quarter worth $200,000.

Camber Capital Management Llc, which manages about $1.75 billion and $1.58B US Long portfolio, upped its stake in Radius Health Inc (NASDAQ:RDUS) by 1.05 million shares to 1.15M shares, valued at $44.33 million in 2017Q3, according to the filing. Riverhead Capital Management LLC now owns 8,754 shares of the biopharmaceutical company's stock worth $171,000 after purchasing an additional 3,854 shares during the last quarter. Northern Trust Corp now owns 1,937,352 shares of the biopharmaceutical company's stock worth $37,877,000 after acquiring an additional 130,294 shares during the last quarter.

The company now has an insider ownership of 1.2 Percent and Institutional ownership of 93.3 Percent.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 83,333 shares of the stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $58.66, for a total value of $1,759,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. $32,863 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Doberstein Stephen K on Wednesday, August 16. Following the transaction, the chief executive officer now owns 272,768 shares in the company, valued at approximately $15,190,449.92. The disclosure for this purchase can be found here.

In related news, major shareholder Cormorant Asset Management, Ll sold 504,027 shares of the stock in a transaction on Thursday, December 14th.

Nexstar Media Group, Inc. (NXST) EPS Estimated At $1.41
Livforsakringsbolaget Skandia Omsesidigt holds 2.07% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 177,764 shares. Emerald Mutual Fund Advisers Trust has invested 0.24% in Nexstar Media Group , Inc. (NASDAQ:NXST) for 17,636 shares.

Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is positive on the stock. Roth Capital set a $45.00 target price on Nektar Therapeutics and gave the stock a "buy" rating in a research report on Monday, November 13th.

Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $85.67, representing a 13.2% upside. Zacks Investment Research raised shares of Nektar Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, January 16th. Canaccord Genuity initiated Nektar Therapeutics (NASDAQ:NKTR) on Thursday, November 9 with "Buy" rating.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold.

Nektar Therapeutics (NASDAQ:NKTR)'s stock has performed at 26.69%. The stock is now moving above its 20-Day Simple Moving Average of 7.23% with a 50-Day Simple Moving Average of 26.35 percent. The company has market cap of $2.15 billion. Nektar Therapeutics has a 12-month low of $12.50 and a 12-month high of $99.02. Interest Gru Incorporated has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). After $0.37 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59% negative EPS growth. The firm had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. Since these figures may be fairly short-term thinking, I have calculated an annualized five-year figure for Nektar Therapeutics's net income, which stands at -US$124.52M.

USA shareholders have been torn between enthusiasm for the massive tax cut passed by Congress past year that could provide a huge stimulus to an economy already at full employment and growing fears that interest rates will jump as the federal government borrows massive amounts to cover its growing deficits. Geode Mgmt Ltd Company reported 1.43 million shares or 0.01% of all its holdings. On average, equities analysts predict that Nektar Therapeutics will post ($0.98) earnings per share for the current fiscal year.

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. It worsened, as 15 investors sold NKTR shares while 52 reduced holdings.

Like this: